1.71
-9.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GRI Bio
From its filings with the US Securities and Exchange Commission
GRI Bio is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GRI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2021, it reported revenue of $0.
We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
Our product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. The active pharmaceutical ingredient in GRI-0621, tazarotene, is a synthetic retinoid acid receptor-beta and gamma selective agonist. Tazarotene is approved in the United States for topical treatment of psoriasis and acne. While there are no approved oral formulations of tazarotene, as of December 31, 2025, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence.
Quoted from its 10-K, filed 30 Jan 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Feb 2021
- Employees
- 2
- Website
- gribio.com ↗
- Head office
- 2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. David SzekeresIndependent Chairman of the Board$91,000
- Dr. W. Marc HertzPresident, Chief Executive Officer, Director, since 2023$617,224
- Ms. Leanne KellyChief Financial Officer$469,420
- Dr. Vipin ChaturvediChief Scientific Officer$419,420
- Dr. Albert AgroChief Medical Officer$406,986
- Mr. David BakerDirector, since 2019$40,000
- Mr. Roelof RongenIndependent Director$57,500
- Ms. Camilla SimpsonIndependent Director$64,500
- Ms. Jenene ThomasIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GRI-0621 is a once-daily oral capsule for fibrotic indications with a focus on IPF treatment.
- GRI Bio Inc. has a pipeline of Natural Killer T modulating therapies targeting inflammatory diseases.
- The company's library of 500+ proprietary compounds addresses high-value indications with unmet need.
Weaknesses
- GRI Bio Inc. employs only 2 full-time employees, limiting operational capacity.
- The company's IPO on 10 February 2021 indicates limited financial resources.
- GRI-0621 is in clinical stages, requiring significant future investment for approval.
Opportunities
- GRI-0803 targets systemic lupus erythematosus, a high-value autoimmune disorder with unmet need.
- The 500+ proprietary compounds library offers potential for multiple therapeutic applications.
- The focus on inflammatory and fibrotic diseases aligns with growing healthcare demands.
Threats
- GRI-0621's clinical-stage development faces regulatory hurdles for IPF treatment approval.
- The small team of 2 employees may struggle with scaling operations and R&D.
- Competition in biotechnology for fibrotic disease treatments remains intense.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.